PDF(Pubmed)
Abstract：
UNASSIGNED: Worldwide, the leading cause of invasive candidiasis and the fourth leading cause of hospital-acquired infections are the Candida species (spp.) group. One of the most important tools in fighting such drug-resistant fungi is the appropriate use of antifungal agents.
UNASSIGNED: The study aimed to determine echinocandins\' general prescribing patterns and how they are associated with the treatment period.
UNASSIGNED: A quantitative, observational, and descriptive was used, and included patients receiving antifungal treatment in a private hospital in Gauteng, South Africa between 01 January 2015 to 31 December 2015.
UNASSIGNED: Of the 146 patient files included, 102 patients (69.9%) received caspofungin and 44 patients (30.1%) were treated with anidulafungin. For the former, 99 (97.1%) patients received a loading dose (LD) of 70 mg, while 200 mg anidulafungin was only prescribed to 30 patients (68.2%). In line with maintenance dose guidelines, the majority (98.1%) of caspofungin-treated patients received 50 mg IV daily, whereas 4 (3.9%) patients were treated at higher doses (70 mg daily). Anidulafungin was administered at various maintenance doses, including 400 mg (2.3% of patients), 200 mg (52.3%), 100 mg (43.2%) and 50 mg (2.3%) IV daily.
UNASSIGNED: Our results can be utilised to produce a hospital-specific algorithm in terms of Candida-infected patients.
UNASSIGNED: These findings contribute to our understanding of prescribing patterns of antifungal agents and the impact thereof on treating Candida spp. Infections.
UNASSIGNED: The study aimed to determine echinocandins\' general prescribing patterns and how they are associated with the treatment period.
UNASSIGNED: A quantitative, observational, and descriptive was used, and included patients receiving antifungal treatment in a private hospital in Gauteng, South Africa between 01 January 2015 to 31 December 2015.
UNASSIGNED: Of the 146 patient files included, 102 patients (69.9%) received caspofungin and 44 patients (30.1%) were treated with anidulafungin. For the former, 99 (97.1%) patients received a loading dose (LD) of 70 mg, while 200 mg anidulafungin was only prescribed to 30 patients (68.2%). In line with maintenance dose guidelines, the majority (98.1%) of caspofungin-treated patients received 50 mg IV daily, whereas 4 (3.9%) patients were treated at higher doses (70 mg daily). Anidulafungin was administered at various maintenance doses, including 400 mg (2.3% of patients), 200 mg (52.3%), 100 mg (43.2%) and 50 mg (2.3%) IV daily.
UNASSIGNED: Our results can be utilised to produce a hospital-specific algorithm in terms of Candida-infected patients.
UNASSIGNED: These findings contribute to our understanding of prescribing patterns of antifungal agents and the impact thereof on treating Candida spp. Infections.
摘要：
■全球，侵袭性念珠菌病的主要原因和医院获得性感染的第四大原因是念珠菌属（spp.)组。对抗这种耐药真菌的最重要工具之一是适当使用抗真菌剂。
■该研究旨在确定棘白菌素的一般处方模式以及它们与治疗期的关系。
■定量的，观察,使用了描述性的，包括在豪登省一家私立医院接受抗真菌治疗的患者，2015年1月1日至2015年12月31日之间的南非。
■在包含的146份患者档案中，102例患者（69.9％）接受了卡泊芬净治疗，44例患者（30.1％）接受了anidulafungin治疗。对于前者,99（97.1％）患者接受了70mg的负荷剂量（LD），而200mganidulafungin仅用于30例患者（68.2％）。根据维持剂量指南，大多数(98.1%)卡泊芬净治疗的患者每天接受50毫克静脉注射，而4例（3.9％）患者接受了较高剂量（每天70mg）的治疗。Anidulafungin以各种维持剂量给药，包括400毫克（2.3%的患者），200毫克（52.3%），每天静脉注射100毫克（43.2％）和50毫克（2.3％）。
■我们的结果可用于产生针对念珠菌感染患者的医院特定算法。
■这些发现有助于我们理解抗真菌剂的处方模式及其对治疗念珠菌的影响。感染。
■该研究旨在确定棘白菌素的一般处方模式以及它们与治疗期的关系。
■定量的，观察,使用了描述性的，包括在豪登省一家私立医院接受抗真菌治疗的患者，2015年1月1日至2015年12月31日之间的南非。
■在包含的146份患者档案中，102例患者（69.9％）接受了卡泊芬净治疗，44例患者（30.1％）接受了anidulafungin治疗。对于前者,99（97.1％）患者接受了70mg的负荷剂量（LD），而200mganidulafungin仅用于30例患者（68.2％）。根据维持剂量指南，大多数(98.1%)卡泊芬净治疗的患者每天接受50毫克静脉注射，而4例（3.9％）患者接受了较高剂量（每天70mg）的治疗。Anidulafungin以各种维持剂量给药，包括400毫克（2.3%的患者），200毫克（52.3%），每天静脉注射100毫克（43.2％）和50毫克（2.3％）。
■我们的结果可用于产生针对念珠菌感染患者的医院特定算法。
■这些发现有助于我们理解抗真菌剂的处方模式及其对治疗念珠菌的影响。感染。
